225 results
Page 4 of 12
8-K
EX-99.1
mc45hv6qv yyz
5 Nov 20
Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection
4:01pm
8-K
EX-99.1
frf6gn9jm8442cv5lw
4 Aug 20
Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe
4:10pm
8-K
EX-10.2
hga d01ku
29 May 20
Departure of Directors or Certain Officers
4:05pm
8-K
EX-10.3
nm3yl203jjgppmfg5
29 May 20
Departure of Directors or Certain Officers
4:05pm
8-K
EX-10.4
glz2rfbz5o 5ts77
29 May 20
Departure of Directors or Certain Officers
4:05pm
8-K
EX-10.1
loi1aq86vgte5y 8bpw
29 May 20
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
1daco9 52d5ag5m
11 May 20
Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives
4:24pm
8-K
EX-10.1
1ojndtzuejlp26tjxag2
27 Apr 20
Entry into a Material Definitive Agreement
5:21pm
8-K
EX-99.1
n1yvjf 0b
27 Apr 20
Entry into a Material Definitive Agreement
5:21pm
424B5
vmem e5hbiz
24 Apr 20
Prospectus supplement for primary offering
5:11pm
8-K
EX-10.2
69d58v46yfsyqvg3
31 Mar 20
Entry into a Material Definitive Agreement
9:03am
424B5
kqbbu
31 Mar 20
Prospectus supplement for primary offering
9:01am
8-K
EX-99.1
fnspev8xqzsm6 6k
28 Feb 20
Strong Q4 2019 revenue growth of 35% driven by a 39% increase in revenue from iCAD’s AI Cancer Detection segment
8:32am
8-K
EX-10.1
uptf6k84z7 2g02eq15
17 Jan 20
Departure of Directors or Certain Officers
4:58pm
8-K
eok8 bnige
17 Jan 20
Departure of Directors or Certain Officers
4:58pm